323 related articles for article (PubMed ID: 3937250)
1. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].
Félez J; Rueda F
Sangre (Barc); 1985; 30(4-C):779-86. PubMed ID: 3937250
[No Abstract] [Full Text] [Related]
2. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
3. Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action.
Gurewich V
Semin Thromb Hemost; 1988 Jan; 14(1):110-5. PubMed ID: 3127884
[No Abstract] [Full Text] [Related]
4. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
Wijngaards G
Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
[TBL] [Abstract][Full Text] [Related]
5. [Anti-activator inhibitors of plasminogen].
Juhan-Vague I; Alessi MC; Aillaud MF
Ann Biol Clin (Paris); 1987; 45(2):202-6. PubMed ID: 3113299
[TBL] [Abstract][Full Text] [Related]
6. Physiological consequences of loss of plasminogen activator gene function in mice.
Carmeliet P; Schoonjans L; Kieckens L; Ream B; Degen J; Bronson R; De Vos R; van den Oord JJ; Collen D; Mulligan RC
Nature; 1994 Mar; 368(6470):419-24. PubMed ID: 8133887
[TBL] [Abstract][Full Text] [Related]
7. [Plasminogen activator inhibitors from neoplastic tissues].
Mirowski M; Wierzbicki R
Postepy Hig Med Dosw; 1991; 45(1-2):119-27. PubMed ID: 1923993
[TBL] [Abstract][Full Text] [Related]
8. Increased plasminogen activator inhibition levels in malignancy.
de Jong E; Knot EA; Piket D; Iburg AH; Rijken DC; Veenhof KH; Dooijewaard G; ten Cate JW
Thromb Haemost; 1987 Apr; 57(2):140-3. PubMed ID: 3110994
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
10. The role of the fibrinolytic system in corneal angiogenesis.
Vogten JM; Reijerkerk A; Meijers JC; Voest EE; Borel Rinkes IH; Gebbink MF
Angiogenesis; 2003; 6(4):311-6. PubMed ID: 15166500
[TBL] [Abstract][Full Text] [Related]
11. [Advances in fibrinolysis mediated by vascular endothelial cells].
Zhou QS
Sheng Li Ke Xue Jin Zhan; 1990 Oct; 21(4):318-22. PubMed ID: 2129251
[No Abstract] [Full Text] [Related]
12. Poly-D-lysine dependent inactivation of tissue plasminogen activator by a class PAI-2 inhibitor (minactivin).
Leung KC; Byatt JA; Stephens RW
Thromb Res; 1987 Jun; 46(6):767-77. PubMed ID: 3114909
[TBL] [Abstract][Full Text] [Related]
13. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Paloma MJ; Páramo JA; Rocha E
Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic system of cultured endothelial cells: regulation by plasminogen activator inhibitor.
Loskutoff DJ; Ny T; Sawdey M; Lawrence D
J Cell Biochem; 1986; 32(4):273-80. PubMed ID: 3100541
[TBL] [Abstract][Full Text] [Related]
16. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (minactivin).
Leung KC; Byatt JA; Stephens RW
Thromb Res; 1987 Jun; 46(6):755-66. PubMed ID: 2957818
[TBL] [Abstract][Full Text] [Related]
17. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo.
Krishnamurti C; Alving BM
Semin Thromb Hemost; 1992 Jan; 18(1):67-80. PubMed ID: 1374195
[No Abstract] [Full Text] [Related]
19. A sensitive assay, specific for endothelial cell type plasminogen activator inhibitor in blood plasma.
Sprengers ED
Thromb Haemost; 1986 Feb; 55(1):74-7. PubMed ID: 3085268
[TBL] [Abstract][Full Text] [Related]
20. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol.
Verheijen JH; Rijken DC; Chang GT; Preston FE; Kluft C
Thromb Haemost; 1984 Jul; 51(3):396-7. PubMed ID: 6437007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
